AI won’t scale without clean data

A lot of drug-company artificial intelligence projects are failing for the same boring reason: the model can read the file, but it cannot tell whether one “sample 42” came from a cell line, a patient visit, or a manufacturing batch. That warning comes from a BioSpace opinion piece by scientists at Charles River Laboratories, which argues that biopharma is generating data faster than it is structuring it. (biospace.com) Artificial intelligence in drug development works less like a genius scientist and more like a very fast intern. If the labels are missing, inconsistent, or trapped in separate systems, the intern can sort papers quickly but still file the wrong experiment with the wrong context. (nist.gov, biospace.com) That context is called metadata, which is just the information attached to the information. In a biopharma lab, metadata can mean the instrument used, the operator, the batch number, the time stamp, the unit of measure, and the exact protocol version behind a result. (fda.gov, biospace.com) The piece argues that a result without metadata is almost useless for reuse. A potency number from one study cannot safely train a model for another team if nobody can trace how the sample was prepared or which assay settings produced it. (biospace.com) This is why the fight is moving from bigger models to cleaner plumbing. The National Institute of Standards and Technology says artificial intelligence standards increasingly need to cover data, performance, and governance, which is another way of saying the system around the model matters as much as the model. (nist.gov, nist.gov) Biopharma has a special version of this problem because its data lives in highly specific software. A laboratory information management system stores lab workflows and sample records, while an electronic batch record tracks how a drug lot was actually made on the manufacturing floor. (biospace.com) If those two systems describe the same material in different ways, the artificial intelligence never sees one continuous story. It sees disconnected snapshots, like trying to predict a movie’s ending from still photos taken by two cameras with different clocks. (biospace.com) The same weakness breaks digital twins, which are software copies of real processes used to simulate what a bioreactor or production line will do next. A digital twin is only as good as the live process data, equipment history, and batch context feeding it. (drugdiscoverynews.com, biospace.com) Regulators have been pushing the industry in this direction for years, even before the current artificial intelligence boom. The Food and Drug Administration’s guidance on current good manufacturing practice says drug records must preserve data integrity, including complete, consistent, and accurate information that can be reviewed and relied on. (fda.gov, fda.gov) That means the glamorous part of artificial intelligence in biopharma may be the least scarce part. The scarcer asset is reusable data that carries its sample, batch, instrument, and process history with it, so one team’s experiment can become another team’s training set instead of another dead file in another silo. (biospace.com, deloitte.com)